Hikma Pharmaceuticals (LON:HIK) Stock Rating Reaffirmed as “Buy” by Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Financial Group in a research report issued on Friday, Digital Look reports. They presently have a GBX 2,025 target price on the stock. Jefferies Financial Group’s target price suggests a potential upside of 27.20% from the company’s previous close.

Several other equities analysts have also issued reports on HIK. Citigroup upped their price target on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Berenberg Bank upped their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Price Performance

Hikma Pharmaceuticals stock traded up GBX 2 during mid-day trading on Friday, hitting GBX 1,592. 409,290 shares of the company were exchanged, compared to its average volume of 4,552,649. The company has a market capitalization of £3.29 billion, a PE ratio of 9.05, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The business has a fifty day moving average of GBX 1,602.90 and a 200 day moving average of GBX 1,478.29. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,865. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57.

Insider Activity at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler purchased 7,500 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is currently owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.